Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996675542> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2996675542 endingPage "141" @default.
- W2996675542 startingPage "133" @default.
- W2996675542 abstract "Study Objectives Immune checkpoint inhibitors have produced durable responses across a variety of cancers. Although programmed cell death protein 1 (PD‐1) and its ligand (PD‐L1) inhibitors activate T cells against tumor cells, they may also cause autoimmune‐like toxicities termed immune‐related adverse events (irAEs). Although much is known regarding irAEs that occur early during treatment, data on the long‐term toxicity profile of these agents are more limited. Our primary objective was to evaluate the frequency of patients receiving anti‐PD‐1/PD‐L1 therapy for at least 6 continuous months who experienced new or worsening irAEs requiring clinical interventions. Secondary objectives included assessment of other factors associated with clinically significant irAEs after at least 6 months of therapy. Design Retrospective chart review. Setting Large university‐affiliated National Cancer Institute–designated comprehensive cancer center. Patients A total of 159 adults diagnosed with any malignancy who received a PD‐1/PD‐L1 inhibitor—nivolumab, pembrolizumab, or atezolizumab—as monotherapy or with concurrent cytotoxic agents, for at least 6 months, between January 1, 2014, and September 1, 2017. Measurements and Main Results We collected information on the incidence and timing of irAEs, along with patient demographics and other treatment outcomes. Thirty‐eight patients (24%) experienced clinically significant, new, or worsening irAEs after 6 months of treatment with anti‐PD‐1/PD‐L1 therapy. Hypothyroidism was the most common irAE experienced (20 patients [12.6%]), followed by pneumonitis (5 patients [3%]); 2 patients died due to pneumonitis. Four patients (2.5%) had a deepened disease response beyond 6 months of treatment. Conclusion Our results revealed that a significant proportion of patients continue to experience irAEs with long‐term use of PD‐1/PD‐L1 inhibitors. These results further contribute to the risk‐benefit understanding of chronic PD‐1/PD‐L1 antagonism and support discontinuation of these agents following deepest response." @default.
- W2996675542 created "2019-12-26" @default.
- W2996675542 creator A5021873644 @default.
- W2996675542 creator A5022272969 @default.
- W2996675542 creator A5043235685 @default.
- W2996675542 creator A5046376020 @default.
- W2996675542 date "2020-01-10" @default.
- W2996675542 modified "2023-09-26" @default.
- W2996675542 title "New and Worsening Long‐term Immune‐Related Adverse Events with PD‐1/PD‐L1 Pathway Agents in Patients with Cancer" @default.
- W2996675542 cites W2125112000 @default.
- W2996675542 cites W2143488876 @default.
- W2996675542 cites W2177405394 @default.
- W2996675542 cites W2179179825 @default.
- W2996675542 cites W2259730793 @default.
- W2996675542 cites W2277326116 @default.
- W2996675542 cites W2338494814 @default.
- W2996675542 cites W2746991247 @default.
- W2996675542 cites W2779503684 @default.
- W2996675542 doi "https://doi.org/10.1002/phar.2354" @default.
- W2996675542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31863604" @default.
- W2996675542 hasPublicationYear "2020" @default.
- W2996675542 type Work @default.
- W2996675542 sameAs 2996675542 @default.
- W2996675542 citedByCount "6" @default.
- W2996675542 countsByYear W29966755422020 @default.
- W2996675542 countsByYear W29966755422021 @default.
- W2996675542 countsByYear W29966755422023 @default.
- W2996675542 crossrefType "journal-article" @default.
- W2996675542 hasAuthorship W2996675542A5021873644 @default.
- W2996675542 hasAuthorship W2996675542A5022272969 @default.
- W2996675542 hasAuthorship W2996675542A5043235685 @default.
- W2996675542 hasAuthorship W2996675542A5046376020 @default.
- W2996675542 hasConcept C121608353 @default.
- W2996675542 hasConcept C126322002 @default.
- W2996675542 hasConcept C143998085 @default.
- W2996675542 hasConcept C197934379 @default.
- W2996675542 hasConcept C2775949291 @default.
- W2996675542 hasConcept C2777701055 @default.
- W2996675542 hasConcept C2777714996 @default.
- W2996675542 hasConcept C2777742743 @default.
- W2996675542 hasConcept C2779399171 @default.
- W2996675542 hasConcept C2779524853 @default.
- W2996675542 hasConcept C2780030458 @default.
- W2996675542 hasConcept C2780057760 @default.
- W2996675542 hasConcept C2781433595 @default.
- W2996675542 hasConcept C71924100 @default.
- W2996675542 hasConceptScore W2996675542C121608353 @default.
- W2996675542 hasConceptScore W2996675542C126322002 @default.
- W2996675542 hasConceptScore W2996675542C143998085 @default.
- W2996675542 hasConceptScore W2996675542C197934379 @default.
- W2996675542 hasConceptScore W2996675542C2775949291 @default.
- W2996675542 hasConceptScore W2996675542C2777701055 @default.
- W2996675542 hasConceptScore W2996675542C2777714996 @default.
- W2996675542 hasConceptScore W2996675542C2777742743 @default.
- W2996675542 hasConceptScore W2996675542C2779399171 @default.
- W2996675542 hasConceptScore W2996675542C2779524853 @default.
- W2996675542 hasConceptScore W2996675542C2780030458 @default.
- W2996675542 hasConceptScore W2996675542C2780057760 @default.
- W2996675542 hasConceptScore W2996675542C2781433595 @default.
- W2996675542 hasConceptScore W2996675542C71924100 @default.
- W2996675542 hasIssue "2" @default.
- W2996675542 hasLocation W29966755421 @default.
- W2996675542 hasOpenAccess W2996675542 @default.
- W2996675542 hasPrimaryLocation W29966755421 @default.
- W2996675542 hasRelatedWork W2968490685 @default.
- W2996675542 hasRelatedWork W3000961096 @default.
- W2996675542 hasRelatedWork W3097089513 @default.
- W2996675542 hasRelatedWork W3103774939 @default.
- W2996675542 hasRelatedWork W3119432592 @default.
- W2996675542 hasRelatedWork W3136244698 @default.
- W2996675542 hasRelatedWork W3142034339 @default.
- W2996675542 hasRelatedWork W3154458198 @default.
- W2996675542 hasRelatedWork W4221003897 @default.
- W2996675542 hasRelatedWork W4283697218 @default.
- W2996675542 hasVolume "40" @default.
- W2996675542 isParatext "false" @default.
- W2996675542 isRetracted "false" @default.
- W2996675542 magId "2996675542" @default.
- W2996675542 workType "article" @default.